IMPORTANCE Assessment of PD-L1 (programmed cell death 1 ligand 1) expression by immunohistochemical analysis has been used as a predictive diagnostic test to identify responders and guide treatment in trials of the PD-1 (programmed cell death 1) axis inhibitors. The definition of PD-L1 positive lacks standardization, and prediction of response by immunohistochemical analysis is additionally limited by the subjective nature of this technique.
A ssessment of PD-L1 (programmed cell death 1 ligand 1) expression by immunohistochemical (IHC) analysis has been used as a predictive diagnostic test to identify responders and guide treatment in trials of the PD-1 (programmed cell death 1) axis inhibitors nivolumab, atezolizumab, durvalumab, and pembrolizumab in non-small cell lung cancer (NSCLC). [1] [2] [3] [4] The PD-L1 IHC 22C3 PharmDx kit (Dako North America) was approved by the US Food and Drug Administration (FDA) as a companion diagnostic for pembrolizumab in NSCLC, whereas the PD-L1 28-8 PharmDx kit (Dako North America) and the PD-L1 SP142 Ventana test (Ventana Medical Systems Inc) were approved as complementary diagnostics for nivolumab and atezolizumab, repectively. The definition of PD-L1 positive lacks standardization, and prediction of response by IHC analysis is additionally limited by the subjective nature of the technique. Variable cutoffs for defining positive cases across trials have been used when measuring tumor and/or immune cells in the stroma. [4] [5] [6] Although some PD-L1 antibodies have been rigorously validated in the published literature, including 28-8 and E1L3N, others are less documented, and specific epitope sequences remain proprietary. 7, 8 Significant differences in case classification have been observed with 2 validated PD-L1 antibodies, indicating that discordance was a function of tissue heterogeneity or variability among the antibodies. 9 To examine the effect of epitope targeting or potential nonspecific binding, we developed a tissue microarray with a range of positive and negative specimens, including tumor, normal tissue, and cell lines (eFigure 1intheSupplement). We analyzed 6 PD-L1 monoclonal antibodies (intracellular and extracellular domain specific) to determine the concordance among antibodies.
Methods
Thirty randomly selected cases of lung cancer resected from January 1, 2008, through December 31, 2009, were obtained from Yale Pathology Archives with a range of expression of PD-L1 as assessed in previous studies. 9, 10 Tissue and cell line blocks, processed identically, were prepared in a tissue microarray format that contained 0.6-mm representative formalinfixed, paraffin-embedded cores in 2-fold redundancy. Gene editing technology (Horizon Discovery Plc) was used to develop a genetically defined 15-spot cell line microarray (CLMA) PD-L1 IHC reference standard with a range of controlled protein expression levels (negative, low, medium, and high proteinexpressing cell lines). Individual cell lines in the 15-spot CLMA were extensively characterized and verified using molecular assays, IHC analysis, and quantitative digital histologic analysis. All patients had signed consent or waiver of consent forms for tissue use, and the study was approved by the Yale Human Investigation Committee. All data were deidentified. Data analysis was performed from September 2015 through May 2016. PD-L1 expression was evaluated by chromogenic IHC analysis and quantitative immunofluorescence (QIF) using 6 monoclonal antibodies raised against PD-L1 as summarized in the Table. Antibodies were titrated at a range of concentrations, and optimal assay concentration was determined using an algorithm that uses signal to noise ratio and dynamic range. We successfully performed QIF for 4 of the 6 antibodies using automated quantitative analysis as previously described. 9 Chromogenic IHC analysis was quantified using the Aperio Positive Pixel Count based on the intensity of membrane staining of respective PD-L1 antibodies using a modified HER2 algorithm. 11 A detailed description of these methods and immunostaining examples are included in eFigure 2 and eFigure 3 in the Supplement.
Results
Correlation among the antibodies was measured by linear regression. Tumor cores had a lower concordance than cell lines,
Key Points
Question Do the 4 drug-matched companion diagnostic antibodies for PD-1 axis therapies all produce the same results?
Findings In this study, 3 key components of diagnostic tests were assessed: the primary antibody, assay-specific variables related to the staining platform, and immunohistochemical assessment of tissue. All antibodies tested were concordant.
Meaning Discordance of the companion diagnostic test is not attributable to the antibody but rather to inherent tumor heterogeneity or assay-or platform-specific variables. 
Discussion
There are currently multiple assays under investigation or approved as companion or complementary diagnostic tests for PD-L1. It is concerning that the FDA clearance of an assay on the basis of assay performance appears to have become more important than the accurate and reproducible measurement of the target. As a result, at least 4 separate antibodies have been included in assays that are part of separate FDA submissions, creating a challenge for pathologists who may need to perform 4 different assays rather than assess PD-L1 expression. Imagine a situation where a pathologist required separate assays for the dozen or so drugs that target the estrogen receptor in breast cancer.
Lung cancer cell lines when tested with the 4 antibodies tested by QIF had high concordance for PD-L1 binding. The Abcam 28-8 antibody elicited reproducible results only when tested on the isogenic cell lines. This finding suggests that 28-8 recognizes PD-L1 in a manner similar to the other antibodies tested. Furthermore, reproducibility in our hands was only seen within a single vial, despite the purchase of 4 vials from the same manufacturer's lot. The E1L3N antibody appears to be the only outlier, with R 2 values as low as 0.42 on tumor specimens. However, high concordance in cell lines and 3,3′-diaminobenzidine assessments and extensive previous validation of E1L3N support the hypothesis that low regressions are a function of tumor heterogeneity. The possibility that E1L3N recognizes a PD-L1 variant or another B7 family member cannot be definitively excluded. 12 Overall, this result indicates the need for a tissue series of the tumor type under investigation to be included in antibody validation. Limitations of this study include the relatively small patient series used, but high levels of concordance and reproducibility among the antibodies suggest that this does not adversely affect the results, except as noted above. Another limitation was our inability to compare 28-8 and 22c3 by QIF. Finally, this work does not define the positive-negative threshold for PD-L1 or the reproducibility of assessment around that threshold. Future work will address the issue of assay threshold reproducibility.
Conclusions
This study provides good evidence that most antibodies used for PD-L1 studies are highly similar in their ability to bind PD-L1. A previous study 9 found approximately 25% discordance between E1L3N and SP142 on tissue specimens quantified in more than 500 fields of view. In that work, the authors concluded, "Objective determination of PD-L1 protein levels in NSCLC reveals heterogeneity within tumors and prominent inter-assay variability." 9(p 46) This new data allow us to suggest that the discordance seen in that study is likely attributable to the high levels of heterogeneity of expression of PD-L1 that has also been described in other works 9,10,13 rather than antibody-based interassay variability. This result suggests that assays based on the use of the antibodies tested should be concordant, barring the substantial effects of the heterogeneity of PD-L1 expression or subjective scoring systems or other assay-or platform-specific variables. 
Introduction
Immune therapies targeting programmed cell death 1(PD-1) and its respective ligand, programmed cell death ligand -1 (PD-L1) have demonstrated objective clinical responses in a variety of advanced tumor types, including NSCLC (1-3). The PD-1/PD-L1 immune checkpoint axis is an important co-regulatory system in the immune response which leads to the inactivation/exhaustion of lymphocyte cells (4) (5) (6) . Its natural function is to down-regulate the immune system response to self-antigens as evidenced by the development of significant autoimmunity in PD-L1 knockout mice (7) . While both of the FDA-approved assays show a higher response rate in PD-L1 positive patients, substantial responses have been observed in PD-L1 negative patients (8) (9) (10) . The definition of PD-L1 positive currently lacks standardization and prediction of response by IHC is limited by the subjective nature of the technique. Variable cutoffs for defining a positive case across trials have been utilized, for instance, the assay coupled with nivolumab uses categories of 0, >1, >5 and >10% cells with membranous staining, while the assay for pembrolizumab uses 0, 1-49, and >50% cells positive (1, 3) . To further complicate the situation, atezolimab and avelumab also assess the expression of PD-L1 in the immune cells in the surrounding stroma (11) (12) (13) .
PD-L1 is a single transmembrane protein with IgV-like and IgC-like extracellular domains, as well as a short 31 amino acid cytoplasmic tail at its C terminus (14) . Antibodies against both intracellular and extracellular domains are available commercially, and it has been reported that antibodies targeting PD-L1's cytoplasmic provide clearer membranous staining (15) . This discrepancy could be explained by differential expression and/or function of PD-L1's intra-and extracellular domains. For instance, an RNA splice variant lacking the extracellular IgV domain has been identified though endogenous expression of a corresponding protein isoform, but this has not been verified in any in vitro or animal models (16) . Theoretically, cleavage of PD-L1 could account for differences in intracellular and extracellular PD-L1 staining. Unpublished data in our lab suggested antibodies directed at the extracellular domain revealed expression in some cases that were negative for the intracellular domain. However subsequent work suggested that antibody (E1J2J) showed lack of specificity in some common assay conditions and thus is was not included in this study. Quantitative Immunofluorescence: TMA slides were soaked in xylene twice for 20 minutes each. Slides were rehydrated in two 1-minute washes in 100% ethanol followed by one wash in 70% ethanol and rinsed in streaming tap water for 5 minutes. Antigen retrieval was performed in EDTA, pH 8 in the Lab Vision PT module. Buffers were preheated to 85 ûC before slide addition and then heated to sub-boiling 97ûC for 20 mins. Endogenous peroxidases were blocked by 30-minute incubation in 2.5% hydrogen peroxide in methanol. Nonspecific antigens were blocked using a 0.3% BSA in TBST for 30 minutes. Primary antibodies were incubated at concentrations described in Table  1 (main text) and 1:100 pan-cytokeratin (Clone AE1/AE3 Dako) overnight at 4 ûC except for SP263 which was incubated for 20 minutes at 37 °C followed by 1hr incubation with pan-cytokeratin. Following this the slides were incubated with Alexa 546-conjugated goat anti mouse secondary antibody (Life Technologies) 1:100 diluted in rabbit EnVision reagent (Dako K4009) for 1 hr at RT. Target signal was amplified using Cy5-Tyramide (Perkin Elmer SAT705A001EA) for 10 mins. Finally, TMAs were stained with 1:500 DAPI for 10 mins at RT and mounted with Prolong Gold antifade mounting reagent (Life Technologies P36394). Immunofluorescence was quantified using automated quantitative analysis (AQUA) on all regions of tissue on each slide as previously described (17) . Briefly, fluorescent images of DAPI, Cy3 (Alexa 546-cytokeratin), and Cy5 (PD-L1) for each core were collected. Image analysis was carried out using the AQUAnalysis software (Genoptix), which is generated for each compartment by dividing the sum of target pixel intensities by the area of the compartment in which the target is measured.
Methods
Quantitation of chromogenic IHC: Chromogenic IHC was quantified using the Aperio Positive Pixel Count based on the intensity of membrane staining of respective PD-L1 antibodies. Intensity as defined in this instance is proportional to the amount of light transmitted through the slide with values ranging from 0-255. Intensity values determined from Positive Pixel Count were subtracted from highest possible intensity (255) to create a directly proportional distribution of membrane intensity for each antibody.
Results

YTMA index array as a standardized PD-L1 array
In an effort to comparatively assess the measurement of PD-L1 across antibodies we constructed a PD-L1 specific index array called YTMA 337 using tumors and cell lines (eFigure 1). Both chromogenic and fluorescent immunostaining were performed. Representative DAB and QIF images of control tissue (placenta), cell lines (H820 and Ramos) and tumor tissue are shown in eFigure 2. Lack of staining in Ramos cell lines and Mel624 WT which are known negatives for PD-L1 was used to confirm specificity of all antibodies tested in this analysis. As expected all staining observed in the controls and tumor tissue was membranous in accordance with known cellular location of PD-L1. Positive staining of PD-L1 was observed in both tumor and stroma of lung cancer cases however only positive staining in tumor was used for determination of optimal antibody concentration.
To determine the optimal antibody concentration for each antibody, we used an algorithm which determines the adjusted signal to noise, based on QIF where signal to noise is calculated by dividing the to 10% of cases by the bottom 10% of cases (assumed to represent noise) then multiplied by the dynamic range as calculated by the difference between the mean of the top and bottom 10% of cases. The optimal concentrations of each of the antibodies in our QIF assay were determined by testing antibody concentrations ranging from one log above to one log below the manufacturers recommended concentration (except for SP263 which was only obtainable in prediluted form). Optimal concentrations, selected based on the adjusted signal to noise ratio were, 3.4, 0.077 and 1.0 µg/ml for E1L3N, SP142 and 9A11 respectively (eFigure 3). SP263 is currently only available as a prediluted antibody at 1.61 µg/ml, therefore we were limited in the dilutions we could perform however we tittered SP263 at three concentrations below the prediluted concentration. At 1.61 g/ml SP263 demonstrated the highest adjusted signal to noise indicating that optimal concentration may be either the pre-diluted concentration or above, however we were unable to confirm due to lack of concentrated antibody. 28-8 showed a lack of reproducibility under QIF conditions in a standard QIF staining protocol (Day 1-3) with Kappa co-efficient ranging from 0.001 to 0.16 (eFigure 4A). We additionally included an assay performed on Bond Rx as per Abcam guidelines (Day 4 Operator 3) and regressed to SP142 (eFigure 4B) for cell lines and tumors. Regressions between SP142 and 28-8 tested on Bond Rx were 0.44 and 0.56 for tumor and cell line cores respectively. Representative Images from 28-8 immunostaining are shown in eFigure 4C. 28-8 results were reproducible under DAB staining of 15 Spot CLMA are described in main text. Representative examples of the DAB for all antibodies is shown in eFigure 5
Chromogen-based assessment of PD-L1 antibody concordance
As demonstrated above 28-8 results were only reproducible under DAB staining conditions. To include this antibody in our comparisons, we utilized the Aperio Positive Pixel counter and assessed DAB staining of the Horizon 15 Spot CLMA array. All staining was carried out in a single run on the Bond Rx as described in materials and methods. Using this method, all five antibodies (E1l3N, SP142, 9A11, SP263 and 28-8) showed high levels of concordance (discussed in main text). A schematic of this array and representative images is shown in eFigure 5. Similarly, antibody 22c3 was evaluable only using the Dako Link 48 platform. A single CLMA slide was run on
